Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide Mechanism in T2D
NCT02773381Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2016
- Primary completion
- Oct 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Area under the serum glucose concentration-time curve at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02773381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773381.